This is a preprint.
Disease-specific selective vulnerability and neuroimmune pathways in dementia revealed by single cell genomics
- PMID: 37808727
- PMCID: PMC10557766
- DOI: 10.1101/2023.09.29.560245
Disease-specific selective vulnerability and neuroimmune pathways in dementia revealed by single cell genomics
Update in
-
Cross-disorder and disease-specific pathways in dementia revealed by single-cell genomics.Cell. 2024 Oct 3;187(20):5753-5774.e28. doi: 10.1016/j.cell.2024.08.019. Epub 2024 Sep 11. Cell. 2024. PMID: 39265576
Abstract
The development of successful therapeutics for dementias requires an understanding of their shared and distinct molecular features in the human brain. We performed single-nuclear RNAseq and ATACseq in Alzheimer disease (AD), Frontotemporal degeneration (FTD), and Progressive Supranuclear Palsy (PSP), analyzing 40 participants, yielding over 1.4M cells from three brain regions ranging in vulnerability and pathological burden. We identify 35 shared disease-associated cell types and 14 that are disease-specific, replicating those previously identified in AD. Disease - specific cell states represent molecular features of disease-specific glial-immune mechanisms and neuronal vulnerability in each disorder, layer 4/5 intra-telencephalic neurons in AD, layer 2/3 intra-telencephalic neurons in FTD, and layer 5/6 near-projection neurons in PSP. We infer intrinsic disease-associated gene regulatory networks, which we empirically validate by chromatin footprinting. We find that causal genetic risk acts in specific neuronal and glial cells that differ across disorders, primarily non-neuronal cells in AD and specific neuronal subtypes in FTD and PSP. These data illustrate the heterogeneous spectrum of glial and neuronal composition and gene expression alterations in different dementias and identify new therapeutic targets by revealing shared and disease-specific cell states.
Similar articles
-
Cross-disorder and disease-specific pathways in dementia revealed by single-cell genomics.Cell. 2024 Oct 3;187(20):5753-5774.e28. doi: 10.1016/j.cell.2024.08.019. Epub 2024 Sep 11. Cell. 2024. PMID: 39265576
-
Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum.JAMA Neurol. 2018 Jul 1;75(7):860-875. doi: 10.1001/jamaneurol.2018.0372. JAMA Neurol. 2018. PMID: 29630712 Free PMC article.
-
Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia.Acta Neuropathol. 2017 May;133(5):825-837. doi: 10.1007/s00401-017-1693-y. Epub 2017 Mar 7. Acta Neuropathol. 2017. PMID: 28271184 Free PMC article.
-
Neuropathology of variants of progressive supranuclear palsy.Curr Opin Neurol. 2010 Aug;23(4):394-400. doi: 10.1097/WCO.0b013e32833be924. Curr Opin Neurol. 2010. PMID: 20610990 Review.
-
Neurofilament Light Chain Levels in Frontotemporal Dementia and Progressive Supranuclear Palsy: A Systematic Review.J Alzheimers Dis. 2022;87(1):131-140. doi: 10.3233/JAD-215616. J Alzheimers Dis. 2022. PMID: 35275542
Cited by
-
MAPT haplotype-associated transcriptomic changes in progressive supranuclear palsy.Acta Neuropathol Commun. 2024 Aug 17;12(1):135. doi: 10.1186/s40478-024-01839-3. Acta Neuropathol Commun. 2024. PMID: 39154163 Free PMC article.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous